(NASDAQ: ACRV) Acrivon Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.55%.
Acrivon Therapeutics's earnings in 2024 is -$69,002,000.On average, 6 Wall Street analysts forecast ACRV's earnings for 2024 to be -$74,435,399, with the lowest ACRV earnings forecast at -$83,934,562, and the highest ACRV earnings forecast at -$69,687,367. On average, 6 Wall Street analysts forecast ACRV's earnings for 2025 to be -$81,664,302, with the lowest ACRV earnings forecast at -$108,712,292, and the highest ACRV earnings forecast at -$66,899,872.
In 2026, ACRV is forecast to generate -$81,998,802 in earnings, with the lowest earnings forecast at -$107,473,406 and the highest earnings forecast at -$57,298,502.